A study titled "Association between e-cigarette use in the United States and vision impairment" analyzed data from 1,173,646 adults between the ages of 18 and 50 over the period of 2016 to 2018. The results indicate that e-cigarette users have a 34% higher likelihood of vision impairment compared to non-users, while former users have a 14% higher likelihood.
A team of researchers have concluded that solvents in e-cigarette liquids may damage tear ducts and cause "oxidative stress" in the body, which is linked to worsening eyesight. Another recent study published in the Nicotine & Tobacco Research journal by the University of California, Los Angeles emphasized the relative safety of smokeless tobacco products and how switching from combustible cigarettes to these products may be associated with a reduced risk of cardiovascular disease among smokers.
A team of researchers from the University of California, Los Angeles, the University of California, San Francisco, Boston University, and the University of Texas at Arlington conducted a study titled "Association of Smokeless Tobacco Use With Increased Cardiovascular Risk: Insights From The Tobacco and Health Study Population Assessment".
As part of the Population Assessment of Tobacco and Health (PATH) study, researchers analyzed data from a nationally representative sample of 4,347 adult participants who provided urine and blood samples during the 2013-14 period. Among this group, 3,034 participants exclusively used traditional cigarettes, 338 exclusively used smokeless tobacco, and 975 had never used any tobacco products.
According to compiled data, despite similar nicotine levels, non-smokers of tobacco have significantly lower disease biomarkers. "Our findings suggest that despite higher nicotine levels, exclusive non-smokers have significantly lower concentrations of inflammation and oxidative stress biomarkers compared to smokers," said Mary Rezk-Hanna, assistant professor of nursing at the University of California, Los Angeles. She added that the levels of these biomarkers in non-smoke tobacco users are similar to those who have never smoked.
Statement
This article is compiled from third-party information and is intended for industry exchange and learning purposes only.
This article does not necessarily reflect the views of 2FIRSTS and the organization cannot confirm the authenticity or accuracy of its content. The translation of this article is solely intended for industry communication and research purposes.
Due to the limitations of the translator's proficiency, the translated article may not accurately convey the original message. Please refer to the original text for accuracy.
2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign related statements and positions.
The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
